StockNews.AI
TVRD
StockNews.AI
4 hrs

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

1. Tvardi shares dropped over 80% after trial data disappointed investors. 2. Faruqi & Faruqi law firm is investigating claims against Tvardi. 3. The Phase 2 trial results failed to meet established goals. 4. The company's data showed inadequate improvement in lung function. 5. Investors are encouraged to contact legal representation regarding losses.

4m saved
Insight
Article

FAQ

Why Very Bearish?

An over 80% drop indicates severe investor loss and market trust erosion. Historical parallels include similar stock reactions following unfavorable clinical trial results.

How important is it?

Legal investigations post-significant stock drop can lead to prolonged reputational damage and influence future valuations.

Why Long Term?

Persistent negative sentiment can hinder recovery as trust and market confidence take time to rebuild.

Related Companies

VRTXAMGNBIIB
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On Monday, October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients’ baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms. To learn more about the Tvardi investigation, go to www.faruqilaw.com/TVRD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1c84fcf7-a77f-4c3f-a1dd-153f7bf3d4ac

Related News